Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Philips and Gibraltar Health Authority Announce 16-year Strategic Partnership

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and the Gibraltar Health Authority, today announced they have signed a long-term strategic partnership continuing their long-standing relationship and marking ambitions to advance radiology and cardiology patient care. As part of the agreement, the building of a brand-new interventional cardiac suite (cath lab) will commence later this year. The construction and installation of this specialist equipment will take approximately 9-12 months and will be accompanied by a service agreement to ensure ongoing maintenance of the equipment.

Gibraltar’s newly improved services will bring sustainable benefits for patients at St Bernard’s Hospital, with developments expected to lead to more cardiac patients receiving local treatment, instead of traveling across the border to neighboring Spain. Expected clinical outcomes include reduced length of stays for such patients, relieving pressure on demand for hospital beds and ambulance transport services, and improvement in 30-day mortality rates.

The new interventional suite will bring St Bernard’s Hospital’s services up to full operating capacity, allowing more patients to receive a range of cardiology treatments such as coronary angioplasty, catheterization to treat artery blockages and minimally invasive replacement of heart valves. In parallel, existing Philips systems within the hospital will be upgraded with the latest technology, including the replacement of equipment in two X-ray rooms, a fluoroscopy room for real-time moving X-ray imagery and ultrasound systems. As part of the agreement, a new CT system will reduce downtime and delays in diagnostics whilst creating opportunities for St Bernard’s cardiology and radiology teams to further expand services. This could see the Gibraltar Health Authority continue to bring care closer to home for future patients, such as through the availability of coronary CT scanning.

Mark Leftwich Managing Director for Philips UK and Ireland…

This new chapter in our partnership with the Gibraltar Health Authority will give both clinicians and the community of Gibraltar access to innovative technologies beyond the next decade.

He added, “For the first time, clinical staff will be able to manage acute cardiac diseases, such as heart attacks, in a purpose-built suite, whilst Philips imaging systems and informatics will enable faster scanning time and enhanced collaboration. This will help create more efficiency and capacity within the departments and improved image quality will support safer diagnosis.”

Professor Patrick Geoghegan OBE, Director General Gibraltar Health Authority said: “We are delighted to renew and strengthen our relationship with Philips with this new partnership. The impact that this new diagnostic equipment will have on our operation and on the quality of care we will be able to provide for our community is huge. Gibraltar Health Authority continues to strive to provide the best healthcare to the people of Gibraltar.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy